Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Palifermin
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

162394-19-6

162394-19-6 structure

162394-19-6 structure

Name: Palifermin
Chemical Name: Palifermin
CAS Number: 162394-19-6
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-10-15 16:30:18
Modify Date: 2024-01-08 17:47:59
Palifermin is the recombinant human keratinocyte growth factor (KGF). Palifermin induces cells growth. Palifermin shows antimucotoxic. Palifermin can be used to decrease the oral mucosal injury induced by cytotoxic therapy[1][2][3].

Name	Palifermin

Description	Palifermin is the recombinant human keratinocyte growth factor (KGF). Palifermin induces cells growth. Palifermin shows antimucotoxic. Palifermin can be used to decrease the oral mucosal injury induced by cytotoxic therapy[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Palifermin (0-100 ng/mL; 48 h) stimulates the growth of TE-8, TE-11 cells[1]. Cell Proliferation Assay[1] Cell Line: TE-1, TE-8, TE-11 cells Concentration: 0, 1, 10 100 ng/mL Incubation Time: 48 h Result: Increased the proliferation for TE-8, TE-11 cells and did not stimulate the growth of TE-1 cells.
In Vivo	Palifermin (10 mg/kg for single dose or 3 mg/kg for 3 times; daily for 3 days) reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats[2]. Palifermin (5 mg/kg; s.c.) shows effectiveness on oral mucositis induced by fractionated irradiation[3]. Animal Model: DA rats[2] Dosage: 10 mg/kg for single dose or 3 mg/kg for 3 times Administration: Daily for 3 days prior to chemotherapy treatment Result: Reduced diarrhea and increased survival following Irinotecan treatment. Animal Model: Mouse with 5*3 Gy/week irradiation (tongue model)[3] Dosage: 5 mg/kg Administration: S.c; at -3, +4, +11 days or +4, +11, +18 days or -3, +4, +11, +18 days Result: Showed effectiveness on oral mucositis (mouse) induced by fractionated irradiation.
References	[1]. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8. [2]. Yoshino M, et al. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol. 2007 Oct;31(4):721-8. [3]. Dörr W, et al. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol. 2005 Apr;75(1):99-105.

No Any Chemical & Physical Properties